Who are Trafermin 0.01% spray's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rolvedon, Tepezza, Oxervate, Lartruvo, Portrazza, Citomix.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trafermin-0-01-spray.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Trafermin 0.01% spray — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trafermin 0.01% spray (Trafermin 0.01% spray) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: growth factor. Area: Wound healing.

phase 3 growth factor FGF-2 Wound healing Small molecule Live · refreshed every 30 min

Target snapshot

Trafermin 0.01% spray (Trafermin 0.01% spray) — Olympus Biotech Corporation. Trafermin is a recombinant human fibroblast growth factor 2 (FGF-2) used to promote wound healing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trafermin 0.01% spray TARGET	Trafermin 0.01% spray	Olympus Biotech Corporation	phase 3	growth factor	FGF-2
Rolvedon	EFLAPEGRASTIM	Spectrum Pharms	marketed	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor	2022-01-01
Tepezza	TEPROTUMUMAB	Horizon Therapeutics Ireland	marketed	Insulin-like Growth Factor-1 Receptor Inhibitor [EPC]	IGF-1R	2020-01-01
Oxervate	CENEGERMIN	Dompe farmaceutici s.p.a.	marketed	Recombinant Human Nerve Growth Factor [EPC]	High affinity nerve growth factor receptor	2017-01-01
Lartruvo	OLARATUMAB	Eli Lilly	marketed	Platelet-derived Growth Factor Receptor alpha Antagonist	Platelet-derived growth factor receptor alpha	2016-01-01
Portrazza	NECITUMUMAB	Eli Lilly Co	marketed	Epidermal Growth Factor Receptor Antagonist [EPC]	Epidermal growth factor receptor	2015-01-01
Citomix	INTERFERON	Bayer Healthcare Pharms	marketed	Lymphocyte Growth Factor [EPC]		2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (growth factor class)

Amgen · 1 drug in this class
Austin Institute for Clinical Research · 1 drug in this class
Olympus Biotech Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trafermin 0.01% spray — Competitive Intelligence Brief. https://druglandscape.com/ci/trafermin-0-01-spray. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing